^
Association details:
Biomarker:PTEN deletion
Cancer:Prostate Cancer
Drug:everolimus (mTOR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)

Excerpt:
Higher serum levels of carboxypeptidase M and apolipoprotein B were predictive for reaching the primary end point. Deletion of PTEN was associated with longer PFS and response. Treatment was associated with a dose-dependent decrease of CD3, CD4, and CD8 T lymphocytes and CD8 proliferation and an increase in regulatory T cells.
DOI:
10.1016/j.eururo.2013.03.040
Trial ID: